Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

How early is early? Experts debate when and how to start HIV treatment

Article Abstract:

Experts at the Eighth International Conference on AIDS urged that HIV therapy be started while the disease is still in its latency stage. Since research has shown that HIV replication is already quite extensive a few weeks after infection, some conferees felt that treatment should be begun when CD4 levels are still high - about 750, instead of 500 as currently prescribed. They also suggested utilizing drug combinations - DDI and AZT or DDC and AZT - as a primary treatment, rather than as a last resort.

Author: Staver, Sari
Publisher: American Medical Association
Publication Name: American Medical News
Subject: Health
ISSN: 0001-1843
Year: 1992
HEALTH SERVICES, Zidovudine, Didanosine

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Citing loss of underground DDC, AIDS activists urge more access

Article Abstract:

AIDS activists call for Hoffmann-La Roche Inc to supply experimental HIV drug, DDC, to more patients. A Food and Drug Administration (FDA) ruling limiting access to a black market form of the antiviral led to the call for liberalizing eligibility rules on patient access. Questions over variations in the black market drug's quality and potency were at issue in the FDA ruling. Hoffman La Roche has asked for FDA approval to market DDC and AZT, and expects an answer mid-year 1992.

Author: Staver, Sari
Publisher: American Medical Association
Publication Name: American Medical News
Subject: Health
ISSN: 0001-1843
Year: 1992
Laws, regulations and rules

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Panel calls for accelerated approval of AIDS drug

Article Abstract:

A Food and Drug Administration advisory panel has called for speedy approval of Hoffman-La Roche Inc's antiretroviral drug dideoxycytidine (DDC). The drug is to be approved for use only in conjunction with zidovudine (AZT) on HIV-infected patients. The recommendation was based on studies showing that this combination of drugs resulted in an increase in CD4 lymphocytes, a marker of efficacy.

Author: Staver, Sari
Publisher: American Medical Association
Publication Name: American Medical News
Subject: Health
ISSN: 0001-1843
Year: 1992
Regulation of agricultural marketing, Investigations, HIV patients, Antiviral agents

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Usage, Drug therapy, AIDS (Disease), Pharmaceutical industry, Product information, United States. Food and Drug Administration, Hoffmann-La Roche Inc., Zalcitabine
Similar abstracts:
  • Abstracts: Antepartum testing in the hypertensive patient: when to begin. part 2 Antepartum surveillance for a history of stillbirth: when to begin?
  • Abstracts: A 52-year-old man with cardiomyopathy and pulmonary disease. A 26-year-old man with pain, erythema, and swelling of the legs
  • Abstracts: Transfer of host T-cell membrane HLA-DR and CD25 to target cells by human retroviruses. Human antibodies to major histocompatibility complex alloantigens mediate lysis and neutralization of HIV-1 primary isolate virions in the presence of complement
  • Abstracts: Dietary intake of marine n-3 fatty acids, fish intake, and the risk of coronary disease among men. What vitamins should I be taking, doctor?
  • Abstracts: RJR Nabisco's cartoon camel promotes Camel cigarettes to children. Recall and eye tracking study of adolescents viewing tobacco advertisements
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.